- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06480058
Predictors of Bariatric Surgery Weight Loss (BariPredict)
Determinants of Eating Disorder Risk in Pre-intervention Bariatric Surgery Candidates.
The aim of the observational cross-sectional study is to determine the prevalence and correlates of disordered eating among candidates for bariatric surgery in the BariPredict cohort.
The study aims to answer the following question on whether the prevalence of disordered eating is higher in individuals that are candidates of bariatric surgery compared to the general population with obesity.
Study Overview
Status
Detailed Description
Participants referred to Jaber Al Ahmad Al Sabah Hospital, Hawalli, Kuwait, for bariatric surgery were consecutively screened for the study.
A cross-sectional analysis was performed on a subgroup of this cohort with complete baseline data. The analysis investigates the influence of psychological factors associated with obesity before bariatric surgery.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Kuwait, Kuwait, P.O. Box 24923, Safa
- Dana AlTarrah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Obesity BMI > 30 kg/m2
- 18 years and older
Exclusion Criteria:
- BMI < 30 kg/m2
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Eating Disorder Screening
Time Frame: 1 Day
|
A validated SCOFF questionnaire will be self-administered to patients attending their first preoperative bariatric surgery appointment.
The SCOFF questionnaire is a simple 5-question test developed to assess the possible presence of an eating disorder.
The S in SCOFF stands for "sick" (to vomit).
The O stands for "one stone" of weight (i.e., 6.35 kg).
The letters C, F and F stand for "control", "fat" and "food" respectively.
Although the SCOFF is not used for diagnostic purposes, a score of 2 or more positive answers raises the index of suspicion of eating disorders, highlighting the need for a more detailed psychological history .The SCOFF has been previously validated in Arab populations.
|
1 Day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anxiety
Time Frame: 1 Day
|
Kuwait University Anxiety Scale (KUAS) The Kuwait University Anxiety Scale will be used to measure level of anxiety. The 20-item scale will capture cognitive/affective anxiety (9 items), subjective anxiety or nervousness (7 items), and somatic anxiety (4 items) [4]. Responses use a 4-point Likert scale ranging from 1=rare, 2=sometimes, 3= often, 4= always to measure the level of anxiety . The cut offs to indicate anxiety include 0 - 21 normal, 22 - 42 mild anxiety, 42 - 63 moderate anxiety, 64 - 84 severe anxiety. |
1 Day
|
|
Depression
Time Frame: 1 Day
|
Beck Inventory Psychological screening and assessment for anxiety and depression will be carried by a clinical psychologist using a validated questionnaire. The Beck Depression inventory which includes a 21-item multiple choice self-report inventory will be used to measure depressive symptoms within the last week. Each question includes a set of 4 possible choices of how a participant may feel. Choices are scored from 0 to 3, increasing in intensity. The cut-offs to indicate depression include 0 - 9 minimal depression, 10 - 18 mild depression, 19 - 29 moderate depression, 30 - 63 severe depression. |
1 Day
|
|
Obesity
Time Frame: 1 Day
|
Height and weight will be measured using standard protocols by a qualified nurse during the patient's preoperative and post-operative appointments.
Body Mass Index (BMI) will be calculated using WHO cut-off points to define obesity.
Obese patients will be divided into different classes of obesity as the following: obese class I (BMI 30 - 34.9 kg/m2), obese class II (35 - 39.9 kg/m2) and obese class III (BMI > 40 kg/m2).
|
1 Day
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023/2323 (Other Identifier: Ministry of Health)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... and other collaboratorsRecruitingType 2 Diabetes | Diabetes Mellitus Type 2Turkey (Türkiye)
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Steno Diabetes Center CopenhagenRecruitingDiabetes | Cognitive Impairment | Type 2 Diabetes | Diabetes Mellitus Type 2 | Cognitive Decline | Type 2 Diabetes Mellitus (T2DM)Denmark